Payment overview · 2025
General Payments
$245.19
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jacqueline Karlin, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MILWAUKEE, WI · NPI 1518519982
Verified facts
What the public records show
CMS Open Payments records show Jacqueline Karlin, APRN received $245.19 in general payments during 2025 across 2 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 50.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $124.50 | 50.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $120.69 | 49.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.19 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $124.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $120.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sertraline Hcl | Sertraline Hcl | 556 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 61 |
| Quetiapine Fumarate | Quetiapine Fumarate | 380 | 50 |
| Lisinopril | Lisinopril | 353 | 46 |
| Gabapentin | Gabapentin | 328 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 294 | 41 |
| Famotidine | Famotidine | 281 | 39 |
| Warfarin Sodium | Warfarin Sodium | 276 | 11 |
| Furosemide | Furosemide | 257 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 36 |
| Donepezil Hcl | Donepezil Hcl | 211 | 30 |
| Eliquis | Apixaban | 208 | 32 |
| Memantine Hcl | Memantine Hcl | 206 | 32 |
| Losartan Potassium | Losartan Potassium | 197 | 34 |
| Metformin Hcl | Metformin Hcl | 192 | 28 |
| Alendronate Sodium | Alendronate Sodium | 190 | 26 |
| Buspirone Hcl | Buspirone Hcl | 186 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 182 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 31 |
| Trazodone Hcl | Trazodone Hcl | 157 | 26 |
| Mirtazapine | Mirtazapine | 146 | 23 |
| Potassium Chloride | Potassium Chloride | 144 | 29 |
| Omeprazole | Omeprazole | 141 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 22 |
| Simvastatin | Simvastatin | 138 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 20 |
| Loperamide | Loperamide Hcl | 122 | 66 |
| Risperidone | Risperidone | 119 | 18 |
| Metformin Hcl Er | Metformin Hcl | 114 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 113 | 15 |
| Tramadol Hcl | Tramadol Hcl | 110 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 28 |
| Jardiance | Empagliflozin | 98 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | suppressed |
| Aripiprazole | Aripiprazole | 90 | 12 |
| Spironolactone | Spironolactone | 80 | 15 |
| Celecoxib | Celecoxib | 75 | 12 |
| Levetiracetam | Levetiracetam | 71 | 12 |
| Torsemide | Torsemide | 69 | 13 |
| Propranolol Hcl | Propranolol Hcl | 68 | suppressed |
| Latanoprost | Latanoprost | 67 | 13 |
| Lorazepam | Lorazepam | 65 | 15 |
| Olanzapine | Olanzapine | 65 | 13 |
| Carvedilol | Carvedilol | 64 | 12 |
| Myrbetriq | Mirabegron | 62 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | suppressed |
| Rivastigmine | Rivastigmine | 61 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 22 |
| Nyamyc | Nystatin | 60 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 14 |
| Nystatin | Nystatin | 50 | 29 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Prednisone | Prednisone | 47 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Naproxen | Naproxen | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 16 |
| Lidocaine | Lidocaine | 39 | 11 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Verapamil Sr | Verapamil Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Ondansetron Odt | Ondansetron | 15 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.19 · 2 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error